Prometheus Laboratories
Prometheus Laboratories is a specialty clinical laboratory dedicated to enabling precision-guided care in Inflammatory Bowel Disease and other GI disorders. They discover, develop, and commercialize testing services that help clinicians improve patient outcomes across the entire patient journey, from disease interception and stratification to therapy selection, optimization, and monitoring. Their mission is to improve healthcare outcomes through innovative and actionable precision medicine testing solutions for immune-mediated inflammatory diseases.
Industries
Nr. of Employees
large (251-1000)
Prometheus Laboratories
Patents
Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
US-11846642-B2
View DetailsMethods for assessing mucosal healing in ulcerative colitis disease patients
US-11796541-B2
View DetailsMethods for prediction of anti-TNF α drug levels and autoantibody formation
US-11435347-B2
View Details
Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
US-11846642-B2
View DetailsMethods for assessing mucosal healing in ulcerative colitis disease patients
US-11796541-B2
View DetailsMethods for prediction of anti-TNF α drug levels and autoantibody formation
US-11435347-B2
View DetailsProducts
Laboratory-developed therapeutic drug monitoring panel for multiple biologics
A clinically validated panel of laboratory assays that measure serum concentrations and antidrug antibodies for several biologic therapies to inform therapeutic monitoring and optimization.
Pharmacokinetic predictive dosing report
A validated predictive report that uses pharmacokinetic inputs to estimate current and alternative dosing regimens and recommend individualized dosing to reach therapeutic targets.
Serum Endoscopic Healing Index (EHI) test
A quantitative serum test reporting an Endoscopic Healing Index score derived from a 13-biomarker algorithm to aid monitoring and treatment decisions in IBD.
Laboratory-developed therapeutic drug monitoring panel for multiple biologics
A clinically validated panel of laboratory assays that measure serum concentrations and antidrug antibodies for several biologic therapies to inform therapeutic monitoring and optimization.
Pharmacokinetic predictive dosing report
A validated predictive report that uses pharmacokinetic inputs to estimate current and alternative dosing regimens and recommend individualized dosing to reach therapeutic targets.
Serum Endoscopic Healing Index (EHI) test
A quantitative serum test reporting an Endoscopic Healing Index score derived from a 13-biomarker algorithm to aid monitoring and treatment decisions in IBD.
Services
Laboratory-performed assays that quantify serum biologic drug levels and anti-drug antibodies for multiple intravenous and subcutaneous biologic agents to inform treatment optimization.
Patient-specific pharmacokinetic analyses that predict drug exposure and provide individualized dosing recommendations to accelerate and optimize biologic therapy (validated for infliximab and adalimumab cohorts).
A laboratory-developed serum test that measures multiple biomarkers and applies an algorithm to generate an Endoscopic Healing Index (EHI) score to help distinguish endoscopic remission from active inflammatory bowel disease.
A prognostic service that integrates serologic and genetic marker status with clinical characteristics to categorize patients into risk strata for short-term disease complications and support clinical decision-making.
Support for at-home or in-clinic capillary blood sample collection workflows validated to correlate with venous blood concentrations for use with therapeutic drug monitoring and PK tests.
Laboratory-performed assays that quantify serum biologic drug levels and anti-drug antibodies for multiple intravenous and subcutaneous biologic agents to inform treatment optimization.
Patient-specific pharmacokinetic analyses that predict drug exposure and provide individualized dosing recommendations to accelerate and optimize biologic therapy (validated for infliximab and adalimumab cohorts).
A laboratory-developed serum test that measures multiple biomarkers and applies an algorithm to generate an Endoscopic Healing Index (EHI) score to help distinguish endoscopic remission from active inflammatory bowel disease.
A prognostic service that integrates serologic and genetic marker status with clinical characteristics to categorize patients into risk strata for short-term disease complications and support clinical decision-making.
Support for at-home or in-clinic capillary blood sample collection workflows validated to correlate with venous blood concentrations for use with therapeutic drug monitoring and PK tests.
Expertise Areas
- Therapeutic drug monitoring (TDM) for biologic therapies
- Precision-guided dosing and pharmacokinetic-guided therapy optimization
- Biomarker-based disease monitoring and index development
- Clinical assay development and laboratory-developed test validation
Key Technologies
- Homogeneous mobility shift assay (HMSA)
- Drug-tolerant antibody detection methods
- Pharmacokinetic (PK) modeling and dosing algorithms
- Serum multiplex biomarker panels
News & Updates
Presentation of data supporting the clinical and economic benefits of their precision-guided care approach in IBD.
Achievement highlighting the extensive coverage and adoption of their therapeutic drug monitoring tests.
Partnership to expand access and develop new testing solutions.
Presentation of data supporting the clinical and economic benefits of their precision-guided care approach in IBD.
Achievement highlighting the extensive coverage and adoption of their therapeutic drug monitoring tests.
Partnership to expand access and develop new testing solutions.